Venetoclax/Venetoclax: Analysis of Prices and Selection in Domestic and International Markets

Venetoclax/Venetoclax, as a selective and highly potent B-cell lymphoma-2 (BCL-2) inhibitor, has been widely recognized as an important drug in the treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML), especially for those complex cases that cannot receive chemotherapy. The drug is also currently being intensively evaluated for its therapeutic efficacy in a variety of hematological malignancies. BCL-2 protein is overexpressed in a variety of cancers, and venetoclax can effectively block BCL-2 signaling, thereby triggering the apoptosis of cancer cells.

In the domestic market, the original drug of Venacla has been successfully launched and provides patients with a variety of specifications to choose from to meet individual needs. In terms of price, depending on the specifications, each box of medicines is priced at approximately RMB 1-4,000. This drug has also been included in the scope of Class B medical insurance, but it should be noted that medical insurance reimbursement is limited to patients diagnosed with adult acute myeloid leukemia. In other cases, they need to purchase it at their own expense.

For patients who are considering purchasing drugs from overseas, the price of the Turkish version of the original drug is relatively high, with a specification of 100mg*112 tablets that costs more than 10,000 yuan per box. However, there are also generic versions of venetoclax on the market, and the main ingredients of these drugs are basically the same as the original drugs. Take the generic drugs produced by a pharmaceutical factory in Laos as an example. Each box contains 120 100mg tablets and the price is only about 2,000 yuan. However, it is important to note that the prices of all these drugs may change as exchange rates fluctuate. From a price point of view, generic drugs are obviously more economical and provide patients with more choices.